PT1488790E - Preparação sólida contendo uma forma de cristal único a de um derivado de ácido tiazolcarboxílico - Google Patents

Preparação sólida contendo uma forma de cristal único a de um derivado de ácido tiazolcarboxílico Download PDF

Info

Publication number
PT1488790E
PT1488790E PT37155868T PT03715586T PT1488790E PT 1488790 E PT1488790 E PT 1488790E PT 37155868 T PT37155868 T PT 37155868T PT 03715586 T PT03715586 T PT 03715586T PT 1488790 E PT1488790 E PT 1488790E
Authority
PT
Portugal
Prior art keywords
single crystal
acid derivative
preparation containing
solid preparation
thiazolecarboxylic acid
Prior art date
Application number
PT37155868T
Other languages
English (en)
Inventor
Michio Iwai
Kazuhiro Nakamura
Masahiko Dohi
Hiroko Mochizuki
Seiji Mochizuki
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28671666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1488790(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of PT1488790E publication Critical patent/PT1488790E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
PT37155868T 2002-03-28 2003-03-28 Preparação sólida contendo uma forma de cristal único a de um derivado de ácido tiazolcarboxílico PT1488790E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002090889 2002-03-28

Publications (1)

Publication Number Publication Date
PT1488790E true PT1488790E (pt) 2014-10-10

Family

ID=28671666

Family Applications (1)

Application Number Title Priority Date Filing Date
PT37155868T PT1488790E (pt) 2002-03-28 2003-03-28 Preparação sólida contendo uma forma de cristal único a de um derivado de ácido tiazolcarboxílico

Country Status (13)

Country Link
US (1) US7361676B2 (pt)
EP (1) EP1488790B1 (pt)
JP (1) JP4084309B2 (pt)
KR (1) KR100981905B1 (pt)
CN (2) CN101836978B (pt)
AU (1) AU2003220909B2 (pt)
CA (1) CA2474674C (pt)
CY (1) CY1115490T1 (pt)
DK (1) DK1488790T3 (pt)
ES (1) ES2505690T3 (pt)
PT (1) PT1488790E (pt)
SI (1) SI1488790T1 (pt)
WO (1) WO2003082279A1 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999065885A1 (en) 1998-06-19 1999-12-23 Teijin Limited Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazole-carboxylic acid and processes for the preparation thereof
CN100430055C (zh) * 2005-11-11 2008-11-05 天津泰普药品科技发展有限公司 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸和聚乙烯吡咯烷酮玻璃态固溶体及其制备方法
CN101812035B (zh) * 2006-09-07 2012-03-21 上海医药工业研究院 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸晶型及其制备方法
CN101139325B (zh) * 2006-09-07 2010-05-12 上海医药工业研究院 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸晶型及其制备方法
EP2101761A4 (en) * 2006-11-13 2010-01-27 Takeda Pharmaceuticals North A METHODS FOR PRESERVING RENAL FUNCTION USING XANTHINE OXYDOREDUCTASE INHIBITORS
CN1970547B (zh) * 2006-12-07 2011-04-06 重庆医药工业研究院有限责任公司 非布司他的晶型及其制备方法
CN102093308B (zh) * 2006-12-07 2012-08-29 重庆医药工业研究院有限责任公司 非布司他的晶型及其制备方法
CN101412700B (zh) * 2007-10-19 2011-06-08 上海医药工业研究院 非布司他的晶型及其制备方法
CN101386605B (zh) * 2008-10-23 2010-09-08 中国科学院上海药物研究所 非布司他新型晶体及其制备方法
CN101474175B (zh) * 2009-01-20 2014-07-02 重庆医药工业研究院有限责任公司 一种高生物利用度非布司他口服固体制剂及其制备方法
CN101780073B (zh) * 2009-01-21 2013-07-03 重庆圣华曦药业股份有限公司 非布司他分散片药物及其制备方法
US20100311756A1 (en) * 2009-01-22 2010-12-09 Takeda Pharmaceuticals North America, Inc. Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
CN102803240A (zh) 2009-06-10 2012-11-28 特瓦制药工业有限公司 非布索坦的晶形
CN102070558B (zh) * 2009-11-23 2012-08-22 欣凯医药化工中间体（上海）有限公司 非布索坦的新晶型及其制备方法
CN101824005B (zh) * 2010-04-27 2012-06-27 上海凯米侬医药科技有限公司 一种非布索坦的晶型q及其制备方法
TW201206502A (en) * 2010-06-16 2012-02-16 Teijin Pharma Ltd Controlled release nucleated tablet
ES2553584T3 (es) 2010-06-25 2015-12-10 Sandoz Ag Polimorfos de Febuxostat
WO2012005359A1 (ja) * 2010-07-09 2012-01-12 帝人ファーマ株式会社 口腔内崩壊錠剤
ES2532210T3 (es) 2010-09-10 2015-03-25 Takeda Pharmaceuticals U.S.A., Inc. Métodos para el tratamiento concomitante de teofilina y febuxostat
EP2502920A1 (en) 2011-03-25 2012-09-26 Sandoz Ag Crystallization process of Febuxostat from A
WO2012153313A1 (en) * 2011-05-11 2012-11-15 Ranbaxy Laboratories Limited Pharmaceutical composition of febuxostat
WO2012168948A2 (en) * 2011-06-06 2012-12-13 Hetero Research Foundation Process for febuxostat
WO2013001441A1 (en) * 2011-06-29 2013-01-03 Ranbaxy Laboratories Limited Dry formulations of febuxostat
WO2013088449A1 (en) 2011-12-16 2013-06-20 Natco Pharma Limited Stable crystal form of febuxostat and process for the preparation thereof
EP2925306A1 (en) 2012-07-12 2015-10-07 Alembic Pharmaceuticals Limited Pharmaceutical composition of febuxostat
EP2692342A1 (en) 2012-07-30 2014-02-05 Interquim, S.A. Process for the preparation of pharmaceutical compositions comprising febuxostat in the form of tablets
US20140051733A1 (en) * 2012-08-14 2014-02-20 Dr. Reddy's Laboratories Ltd. Febuxostat pharmaceutical compositions
WO2014057461A1 (en) 2012-10-11 2014-04-17 Ranbaxy Laboratories Limited Process for the preparation of crystalline form g of febuxostat
WO2014125504A2 (en) * 2013-02-18 2014-08-21 Hetero Research Foundation Pharmaceutical compositions of febuxostat
CA2913755A1 (en) 2013-05-31 2014-12-04 Teijin Pharma Limited Methods of treatment and compositions with xanthine oxidase inhibitors
CN103588723B (zh) * 2013-09-10 2015-05-20 杭州华东医药集团新药研究院有限公司 一种非布司他晶型a的制备方法
CN103588724B (zh) * 2013-09-10 2015-05-20 杭州华东医药集团新药研究院有限公司 一种非布司他晶型a及其制备方法
JP6283371B2 (ja) * 2013-10-22 2018-02-21 日本ケミファ株式会社 ２−［３−シアノ−４−（２−メチルプロポキシ）フェニル］−４−メチルチアゾール−５−カルボン酸の小型化結晶、その微粉化物及びこれらを含有する固形製剤
EP2881116A1 (en) 2013-12-05 2015-06-10 Ranbaxy Laboratories Limited Febuxostat composition
EP2902016A1 (en) 2014-01-30 2015-08-05 Alfred E. Tiefenbacher (GmbH & Co. KG) Febuxostat tablet
CZ27857U1 (cs) 2014-12-12 2015-02-23 Zentiva, K.S. Formulace obsahující tuhý roztok febuxostatu
JP7164926B2 (ja) * 2015-04-22 2022-11-02 日本ケミファ株式会社 ２－［３－シアノ－４－（２－メチルプロポキシ）フェニル］－４－メチルチアゾール－５－カルボン酸の結晶、その製造方法、及びそれらの利用
GR1009119B (el) * 2016-06-30 2017-09-18 "Φαρματεν Α.Β.Ε.Ε." Φαρμακευτικο σκευασμα περιεχον ενα μη πουρινικο επιλεκτικο αναστολεα της οξειδασης της ξανθινης και μεθοδος παρασκευης αυτου
CN106511288A (zh) * 2016-12-20 2017-03-22 天津泰普制药有限公司 一种非布司他片剂的制备方法
EP3538971A4 (en) 2017-04-25 2020-06-24 Hewlett-Packard Development Company, L.P. FLUID TURBINE CONTROL DEVICE
JP2019142814A (ja) * 2018-02-21 2019-08-29 大原薬品工業株式会社 フェブキソスタット含有錠剤の製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU645867B2 (en) 1990-11-30 1994-01-27 Teijin Pharma Limited 2-arylthiazole derivative and pharmaceutical composition containing the same
WO1996031211A1 (fr) * 1995-04-07 1996-10-10 Teijin Limited Agent protecteur pour organe ou tissu
KR19990082174A (ko) * 1996-02-02 1999-11-25 니뽄 신야쿠 가부시키가이샤 이소퀴놀린 유도체 및 의약
WO1999065885A1 (en) * 1998-06-19 1999-12-23 Teijin Limited Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazole-carboxylic acid and processes for the preparation thereof
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet

Also Published As

Publication number Publication date
EP1488790A4 (en) 2007-06-20
ES2505690T3 (es) 2014-10-10
SI1488790T1 (sl) 2014-09-30
WO2003082279A1 (fr) 2003-10-09
CN101836978A (zh) 2010-09-22
KR100981905B1 (ko) 2010-09-13
KR20040101284A (ko) 2004-12-02
CN1642546A (zh) 2005-07-20
AU2003220909A1 (en) 2003-10-13
US20050043375A1 (en) 2005-02-24
JPWO2003082279A1 (ja) 2005-07-28
DK1488790T3 (da) 2014-10-13
CY1115490T1 (el) 2017-01-04
AU2003220909B2 (en) 2008-09-18
CA2474674A1 (en) 2003-10-09
JP4084309B2 (ja) 2008-04-30
CN101836978B (zh) 2013-09-11
EP1488790A1 (en) 2004-12-22
CA2474674C (en) 2011-04-19
US7361676B2 (en) 2008-04-22
EP1488790B1 (en) 2014-07-16

Similar Documents

Publication Publication Date Title
SI1488790T1 (sl) Trden pripravek, ki vsebuje eno samo kristalno a-obliko derivata tiazolkarboksilne kisline
AU2003211131A1 (en) Metformin salts of lipophilic acids
HK1077830A1 (en) Crystals of glucopyranosyloxybenzyl benzene derivative
AP1967A (en) Thiazolidinone compounds as inhibitors of Hyak3
IL213806A0 (en) Use of derivatives of n-phenylpiperazin-1-yl-acetamide for the preparation of a pharmaceutical compositions for treatment of diabetes related conditions
AU2003255982A1 (en) Preparation of microcapsules
IL174592A0 (en) Processes for the preparation of a polymorph of fluvastantin sodium
AU2002330453A1 (en) Crystals of hydroxynorephedrine derivative
AU2003224781A1 (en) Crystalline forms of rabeprazole sodium
AU2003274518A8 (en) A process for the preparation of benzyl 2-oxo-4- (heteroaryl) dithio-alpha-isoprenyl-1- azetidineazetate derivatives
AU2003253460A1 (en) Crystalline organic acid salt of amlodipine
AU2003260813A8 (en) Improved process for preparation of thiazolidinedione derivatives
AU2003202872A1 (en) Preparation of nano-sized crystals
AU2003212351A8 (en) A process for the preparation of cephalosporan acid derivatives from cephalosporin c
HK1078853A1 (en) A new process for the preparation of epothilone derivatives
EP1486485A4 (en) NEW 5-HYDROXYCARBAMIMIDOYL-2-HYDROXYBENZENESULFONAMIDE DERIVATIVE CRYSTALS
AU2003299746A1 (en) Total synthesis of daurichromenic acid
AU2003231527A8 (en) Novel derivatives of carnosic acid
IL166778A0 (en) Derivatives of gl ycinergic r(+)-2-amino-3-hydroxypropanoic acid
AU2003242538A1 (en) Use of 2-oxo-1-pyrrolidone derivatives for the preparation of a drug
AU2003243153A1 (en) Novel crystalline polymorph form-vi of olanzapine and a process for preparation thereof
AU2003298248A1 (en) A process for the preparation of benzo(d)isoxazol-3-yl-methanesulfonic acid and the intermediates thereof
AU2003258982A1 (en) Methods of inhibiting pin1-associated states using a fredericamycin a compound
IL166599A0 (en) Crystalline solid form of (2s-5z)-2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid
AU2002304385A1 (en) A new process for the preparation of cefditoren using the thioester of thiazolylacetic acid